Compare CCB & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCB | PCRX |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2018 | 2010 |
| Metric | CCB | PCRX |
|---|---|---|
| Price | $40.54 | $25.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $51.00 | $30.00 |
| AVG Volume (30 Days) | 174.6K | ★ 424.0K |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $15.99 | $3.85 |
| Revenue Next Year | $18.21 | $4.69 |
| P/E Ratio | ★ N/A | $134.42 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $35.56 | $18.80 |
| 52 Week High | $120.05 | $27.66 |
| Indicator | CCB | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 33.06 | 51.01 |
| Support Level | $36.61 | $22.13 |
| Resistance Level | $50.78 | $27.03 |
| Average True Range (ATR) | 1.90 | 0.84 |
| MACD | -0.36 | 0.05 |
| Stochastic Oscillator | 31.57 | 68.38 |
Coastal Financial Corp is a bank holding company. Through its subsidiaries, the company conducts its business in three reportable segments which include, Community Bank, CCBX, and Treasury and Administration. The Community Bank segment includes all community banking activities, with a primary focus on providing various banking products and services to consumers and small to medium-sized businesses. The CCBX segment provides Banking as a Service (BaaS) that allows its broker dealers and digital financial service partners to offer their customers banking services, and the Treasury and administration segment includes treasury management, overall administration, and all other aspects of the company.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.